Hair growth abnormal adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 6,807 adverse event reports that record the MedDRA preferred term Hair growth abnormal. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 363 reports in the 12 months to June 2026 and 332 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 1,146 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 363 (under 0.1%) record this term. Reports for female patients were 69.8% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 118 drug pages with 10 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Hair growth abnormal name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		17
Anastrozole	Aromatase inhibitor	34
Androgel		170
Androgel 1%		16
Arimidex	Aromatase inhibitor	52
Aripiprazole	Atypical antipsychotic	12
Aubagio	Pyrimidine synthesis inhibitor	24
Avodart		24
Axiron		19
Ayvakit	Kinase inhibitor	12
Cibinqo	Janus kinase inhibitor	13
Ciprofloxacin	Fluoroquinolone antibacterial	10
Corticotropin		16
Cosentyx	Interleukin-17A antagonist	34
Crestor	HMG-CoA reductase inhibitor	15
Cyclophosphamide	Alkylating drug	23
Cyclosporine	Calcineurin inhibitor immunosuppressant	18
Cymbalta		10
Depo-Provera	Progestin	10
Diazepam	Benzodiazepine	15
Diazoxide choline		18
Docefrez		22
Docetaxel	Microtubule inhibitor	198
Docetaxel Accord		13
Docetaxel Actavis		10
Docetaxel Hospira		12
Docetaxel Pfizer		10
Doxorubicin	Anthracycline topoisomerase inhibitor	14
Dupixent	Interleukin-4 receptor alpha antagonist	112
Eligard	Gonadotropin releasing hormone receptor agonist	23
Eliquis	Factor Xa inhibitor	11
Emflaza	Corticosteroid	19
Enbrel	Tumor necrosis factor blocker	58
Erbitux	Epidermal growth factor receptor antagonist	26
Erivedge	Hedgehog pathway inhibitor	27
Erlotinib	Kinase inhibitor	21
Estradiol	Estrogen	20
Etoposide	Topoisomerase inhibitor	11
Finasteride	5-alpha reductase inhibitor	28
Forteo	Parathyroid hormone analog	84
Gabapentin	Anti-epileptic agent	23
Gilotrif	Kinase inhibitor	13
Herceptin	HER2/neu receptor antagonist	26
Humira		96
Ibrance	Kinase inhibitor	92
Imbruvica	Kinase inhibitor	30
Iressa	Kinase inhibitor	17
Jakafi	Janus kinase inhibitor	15
Keytruda	Programmed death Receptor-1 blocking antibody	12
Kisqali	Kinase inhibitor	27
Lamotrigine	Anti-epileptic agent	12
Latisse	Prostaglandin analog	147
Latisse 0 03%		57
Lipitor	HMG-CoA reductase inhibitor	13
Lisdexamfetamine dimesylate	Central nervous system stimulant	12
Lumigan	Prostaglandin analog	31
Lupkynis	Calcineurin inhibitor immunosuppressant	26
Lupron Depot		13
Lyrica		24
Mens Rogaine		49
Mens Rogaine Extra Strength		355
Methotrexate	Folate analog metabolic inhibitor	15
Minoxidil	Arteriolar vasodilator	120
Mirena	Progestin	103
Nexplanon	Progestin	26
Niraparib	Poly(ADP-Ribose) polymerase inhibitor	24
Nutropin Aq		12
Ocrevus	CD20-directed cytolytic antibody	12
Orserdu	Estrogen receptor antagonist	12
Otezla	Phosphodiesterase 4 inhibitor	17
Paclitaxel	Microtubule inhibitor	16
Pegasys	Interferon alpha	11
Perjeta	HER2/neu receptor antagonist	15
Pomalyst	Thalidomide analog	13
Prednisolone	Corticosteroid	11
Prednisone	Corticosteroid	57
Pregabalin		23
Premarin	Estrogen	12
Prolia	RANK ligand inhibitor	20
Propecia	5-alpha reductase inhibitor	17
Qinlock	Kinase inhibitor	10
Revlimid	Thalidomide analog	85
Rinvoq	Janus kinase inhibitor	14
Risperdal	Atypical antipsychotic	10
Rituximab	CD20-directed cytolytic antibody	18
Rogaine		112
Rubraca	Poly(ADP-Ribose) polymerase inhibitor	11
Sertraline	Serotonin reuptake inhibitor	16
Skyrizi	Interleukin-23 antagonist	11
Sutent	Kinase inhibitor	11
Synthroid	l-Thyroxine	16
Tacrolimus	Calcineurin inhibitor immunosuppressant	13
Tagrisso	Kinase inhibitor	12
Tarceva		123
Tarpeyo	Corticosteroid	31
Taxotere		138
Tecfidera		16
Tepezza		19
Teriflunomide	Pyrimidine synthesis inhibitor	10
Testosterone	Androgen	28
Triptodur		34
Triptorelin pamoate		14
Triptorelin Pamoate - Bp		10
Trulicity	GLP-1 receptor agonist	14
Tymlos		25
Tysabri	Integrin receptor antagonist	21
Vaniqa		30
Vectibix	Epidermal growth factor receptor antagonist	20
Vincristine		11
Vykat Xr		20
Womens Rogaine		244
Womens Rogaine Unscented	Arteriolar vasodilator	523
Xalatan	Prostaglandin analog	18
Xarelto	Factor Xa inhibitor	22
Xeljanz	Janus kinase inhibitor	186
Xolair	Anti-IgE	14
Xyrem	Central nervous system depressant	14
Zejula	Poly(ADP-Ribose) polymerase inhibitor	40

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 32 pharmacologic classes with 25 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Hair growth abnormal name, in order of name
Class	Reports with this term
5-alpha reductase inhibitor	55
Alkylating drug	32
Androgen	45
Anti-epileptic agent	54
Aromatase inhibitor	105
Arteriolar vasodilator	645
Atypical antipsychotic	73
Calcineurin inhibitor immunosuppressant	68
CD20-directed cytolytic antibody	35
Corticosteroid	166
Epidermal growth factor receptor antagonist	48
Estrogen	45
Factor Xa inhibitor	33
GLP-1 receptor agonist	30
Gonadotropin releasing hormone receptor agonist	35
Hedgehog pathway inhibitor	27
HER2/neu receptor antagonist	41
HMG-CoA reductase inhibitor	32
Interleukin-17A antagonist	39
Interleukin-4 receptor alpha antagonist	112
Janus kinase inhibitor	245
Kinase inhibitor	321
Microtubule inhibitor	217
Nucleoside metabolic inhibitor	38
Parathyroid hormone analog	84
Poly(ADP-Ribose) polymerase inhibitor	84
Progestin	144
Prostaglandin analog	206
Pyrimidine synthesis inhibitor	34
Serotonin reuptake inhibitor	36
Thalidomide analog	107
Tumor necrosis factor blocker	94

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Hair growth abnormal, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Hair growth abnormal
Age	Reports	Share
Under 2	26	0.4%
2 to 11	160	2.4%
12 to 17	63	0.9%
18 to 44	845	12.4%
45 to 64	1,178	17.3%
65 to 74	732	10.8%
75 and over	524	7.7%
Age not given	3,279	48.2%

Sex of the patient in the reports that record Hair growth abnormal
Sex	Reports	Share
Female	4,753	69.8%
Male	1,352	19.9%
Unknown or not given	702	10.3%

Age and sex are as the report gives them. 83.9% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Hair growth abnormal: adverse event reports that record this term. https://reportedreactions.com/reaction/hair-growth-abnormal/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Hair growth abnormal mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page